Anaplastic oligodendroglial tumours are chemosensitive tumours—a fact that has been known for almost 25 years. The role and optimal timing of chemotherapy, however, has remained a subject of debate. Long-term results of two phase III trials now show that, in patients with 1p19q-codeleted tumours, early chemotherapy increases overall survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cairncross, J. G. & Macdonald, D. R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360–364 (1988).
Cairncross, J. G. et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90, 1473–1479 (1998).
Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.43.2674.
van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.43.2229.
Cairncross, G. et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24, 2707–2714 (2006).
van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715–2722 (2006).
Lassman, A. B. et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 13, 649–659 (2011).
Bettegowda, C. et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333, 1453–1455 (2011).
Jiao, Y. et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 3, 709–722 (2012).
Sanson, M. et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150–4154 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ducray, F., Idbaih, A. Anaplastic oligodendrogliomas—value of early chemotherapy. Nat Rev Neurol 9, 7–8 (2013). https://doi.org/10.1038/nrneurol.2012.248
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.248
This article is cited by
-
Remote brain microhaemorrhages may predict haematoma in glioma patients treated with radiation therapy
European Radiology (2018)
